---
title: Mini-consolidations or intermediate-dose cytarabine for the post-remission
  therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries
date: '2024-11-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39555737/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241118172049&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: According to current recommendations, older AML patients in first complete
  remission (CR) after induction chemotherapy should receive consolidation with intermediate-dose
  cytarabine (IDAC). However, no study has demonstrated the superiority of IDAC over
  other regimen. In this retrospective study, we compared the efficacy of mini-consolidations
  (idarubicin 8 mg/m² day 1, cytarabine 50 mg/m²/12 h, day 1-5) and IDAC. Inclusion
  criteria were newly diagnosed AML, age > 60 years, first CR ...
disable_comments: true
---
According to current recommendations, older AML patients in first complete remission (CR) after induction chemotherapy should receive consolidation with intermediate-dose cytarabine (IDAC). However, no study has demonstrated the superiority of IDAC over other regimen. In this retrospective study, we compared the efficacy of mini-consolidations (idarubicin 8 mg/m² day 1, cytarabine 50 mg/m²/12 h, day 1-5) and IDAC. Inclusion criteria were newly diagnosed AML, age > 60 years, first CR ...